A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy

References

• Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Current medicinal chemistry. 2006;13: 1859–76.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A cancer journal for clinicians. 2009;59:225–49.
   PubMed Web of Science ®Google Scholar
• Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nature medicine. 2001;7:781–7.
   PubMed Web of Science ®Google Scholar
• Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia. 2008;22:361–9.
   PubMed Web of Science ®Google Scholar
• Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer gene therapy. 2009;16:473–88.
   PubMed Web of Science ®Google Scholar
• Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 2004;39:1371–81.
   PubMed Web of Science ®Google Scholar
• Pan Q, Liu B, Liu J, Cai R, Liu X, Qian C. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta oncologica. 2008;47:135–44.
   PubMed Web of Science ®Google Scholar
• Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Human gene therapy. 2005;16:845–58.
   PubMed Web of Science ®Google Scholar
• Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene therapy. 2008;15:484–94.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, Wang Y, Qian Q, Qian C, Wu J, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer research. 2006;66:4291–8.
   PubMed Web of Science ®Google Scholar
• Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Molecular therapy: the journal of the American Society of Gene Therapy. 2003;7:755–64.
   PubMed Web of Science ®Google Scholar
• Ren Z, Ye X, Fang C, Lu Q, Zhao Y, Liu F, Liang M, Hu F, Chen HZ, et al. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response. Cancer biology & therapy. 2008;7:191–95.
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17:614–22.
   PubMed Web of Science ®Google Scholar
• Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, Burke PJ, Connors TA, Hart IR. Investigation of alternative prodrugs for use with E. coli nitroreductase in ‘suicide gene’ approaches to cancer therapy. Gene therapy. 1996;3:1143–50.
   Google Scholar
• Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). International journal of oncology. 2002;21:1161–74.
   PubMed Web of Science ®Google Scholar
• Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. International journal of cancer. 2004;110:475–80.
   PubMed Web of Science ®Google Scholar
• Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular vision. 2008;14:2535–46.
   PubMed Web of Science ®Google Scholar
• Ballard EN, Trinh VT, Hogg RT, Gerard RD. Peptide targeting of adenoviral vectors to augment tumor gene transfer. Cancer gene therapy. 2012;19:476–88.
   PubMed Web of Science ®Google Scholar
• Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002;8:275–80.
   PubMed Web of Science ®Google Scholar
• Matsui H, Sakurai F, Katayama K, Kurachi S, Tashiro K, Sugio K, Kawabata K, Mizuguchi H. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob. Virus research. 2011;155:48–54.
   PubMed Web of Science ®Google Scholar
• Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of virology. 1997;71:8798–807.
   PubMed Web of Science ®Google Scholar
• Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Human gene therapy. 1999;10:965–76.
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenoviral vectors. Hum Gene Ther. 2004;15:1157–66.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ni S, Lieber A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. Journal of immunology. 2005;174:7310–9.
   PubMed Web of Science ®Google Scholar
• Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Human gene therapy. 2005;16:664–77.
   PubMed Web of Science ®Google Scholar
• DiPaolo N, Ni S, Gaggar A, Strauss R, Tuve S, Li ZY, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Molecular therapy: the journal of the American Society of Gene Therapy. 2006;13:756–65.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez-Edick M, Gibbons D, Waugh J, Van Roey M, Jooss K. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice. Human gene therapy. 2009;20:1201–13.
   PubMed Web of Science ®Google Scholar
• Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene therapy. 2001;8:930–7.
   PubMed Web of Science ®Google Scholar
• Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, Sova P, Morihara J, Feng Q, Kiviat N, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer gene therapy. 2006;13:1072–81.
   PubMed Web of Science ®Google Scholar
• Shinozaki K, Suominen E, Carrick F, Sauter B, Kahari VM, Lieber A, Woo SL, Savontaus M. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene therapy. 2006;13:52–9.
   PubMed Web of Science ®Google Scholar
• Toivonen R, Koskenvuo J, Merentie M, Soderstrom M, Yla-Herttuala S, Savontaus M. Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5. Virology journal. 2012;9:296.
   PubMed Web of Science ®Google Scholar
• Lindert S, Silvestry M, Mullen TM, Nemerow GR, Stewart PL. Cryo-electron microscopy structure of an adenovirus-integrin complex indicates conformational changes in both penton base and integrin. Journal of virology. 2009;83:11491–501.
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. The Journal of cell biology. 1994;127:257–64.
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309–19.
   PubMed Web of Science ®Google Scholar
• Kelkar SA, Pfister KK, Crystal RG, Leopold PL. Cytoplasmic dynein mediates adenovirus binding to microtubules. Journal of virology. 2004;78:10122–32.
   PubMed Web of Science ®Google Scholar
• D'Ambrosio E, Del Grosso N, Chicca A, Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. The Journal of hygiene. 1982;89:155–61.
   PubMedGoogle Scholar
• Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. Human gene therapy. 2015;26:320–9.
   PubMed Web of Science ®Google Scholar
• Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clinical and diagnostic laboratory immunology. 2004;11:351–7.
   PubMedGoogle Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of virology. 2003;77:8263–71.
   PubMed Web of Science ®Google Scholar
• Mizuguchi H, Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene. 2002;285:69–77.
   PubMed Web of Science ®Google Scholar
• Koizumi N, Mizuguchi H, Kondoh M, Fujii M, Hayakawa T, Watanabe Y. Efficient gene transfer into human trophoblast cells with adenovirus vector containing chimeric type 5 and 35 fiber protein. Biological & pharmaceutical bulletin. 2004;27:2046–8.
   PubMed Web of Science ®Google Scholar
• Acharya B, Terao S, Suzuki T, Naoe M, Hamada K, Mizuguchi H, Gotoh A. Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins. Experimental and therapeutic medicine. 2010;1:537–40.
   PubMed Web of Science ®Google Scholar
• Toivonen R, Mayranpaa MI, Kovanen PT, Savontaus M. Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart. Histochemistry and cell biology. 2010;133:349–57.
   PubMed Web of Science ®Google Scholar
• Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Uzawa K, Tanzawa H, Shimada H, Ochiai T, et al. Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncology reports. 2005;14:831–5.
   PubMed Web of Science ®Google Scholar
• Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer research. 2007;27:2311–6.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. Journal of virology. 2005;79:1053–61.
   PubMed Web of Science ®Google Scholar
• Matsui H, Sakurai F, Kurachi S, Tashiro K, Sugio K, Kawabata K, Yamanishi K, Mizuguchi H. Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene therapy. 2009;16:1050–7.
   PubMed Web of Science ®Google Scholar
• Boturyn D, Coll JL, Garanger E, Favrot MC, Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. Journal of the American Chemical Society. 2004;126:5730–9.
   PubMed Web of Science ®Google Scholar
• Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17:837–43.
   PubMed Web of Science ®Google Scholar
• Ye Y, Bloch S, Xu B, Achilefu S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. Journal of medicinal chemistry. 2006;49:2268–75.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Li Z, Tuve S, Stone D, Kalyushniy O, Shayakhmetov D, Verlinde CL, Stehle T, McVey J, et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. Journal of virology. 2008;82:10567–79.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer research. 2002;62:1063–8.
   PubMed Web of Science ®Google Scholar
• Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved–deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Human gene therapy. 2001;12:1323–32.
   PubMed Web of Science ®Google Scholar
• Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H, Pipiya T, Rom WN, Hay JG. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Human gene therapy. 2003;14:425–33.
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nature reviews Cancer. 2005;5:965–76.
   PubMed Web of Science ®Google Scholar
• Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Human gene therapy. 2000;11:2219–30.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008;14:3933–41.
   PubMed Web of Science ®Google Scholar
• Victor R, Chauzy C, Girard N, Gioanni J, d'Anjou J, Stora De Novion H, Delpech B. Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. International journal of cancer. 1999;82:77–83.
   PubMed Web of Science ®Google Scholar
• Shuster S, Frost GI, Csoka AB, Formby B, Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. International journal of cancer. 2002;102:192–7.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. The Journal of biological chemistry. 1990;265:10681–5.
   PubMed Web of Science ®Google Scholar
• Binder C, Hagemann T, Husen B, Schulz M, Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Molecular human reproduction. 2002;8:789–96.
   PubMed Web of Science ®Google Scholar
• Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G, Trümper L, Einspanier A. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast cancer research and treatment. 2004;87:157–66.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews Cancer. 2002;2:161–74.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, Yun CO, Jooss K. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer research. 2007;67:4399–407.
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology. 2007;81:4654–63.
   PubMed Web of Science ®Google Scholar
• Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of virology. 2009;83:479–83.
   PubMed Web of Science ®Google Scholar
• Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer gene therapy. 2016;23:229–34.
   PubMed Web of Science ®Google Scholar
• Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL, Shayakhmetov DM. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:5483–8.
   PubMed Web of Science ®Google Scholar
• Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397–409.
   PubMed Web of Science ®Google Scholar
• Atoda H, Ishikawa M, Mizuno H, Morita T. Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry. 1998;37:17361–70.
   PubMedGoogle Scholar
• Liu Y, Wang H, Yumul R, Gao W, Gambotto A, Morita T, Baker A, Shayakhmetov D, Lieber A. Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Human gene therapy. 2009;20:621–9.
   PubMed Web of Science ®Google Scholar
• Greig JA, Buckley SM, Waddington SN, Parker AL, Bhella D, Pink R, Rahim AA, Morita T, Nicklin SA, McVey JH, et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17:1683–91.
   PubMed Web of Science ®Google Scholar
• Miyazawa N, Crystal RG, Leopold PL. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. Journal of virology. 2001;75:1387–400.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H, Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. Journal of virology. 2003;77:3712–23.
   PubMed Web of Science ®Google Scholar
• Colin M, Renaut L, Mailly L, D'Halluin JC. Factors involved in the sensitivity of different hematopoietic cell lines to infection by subgroup C adenovirus: implication for gene therapy of human lymphocytic malignancies. Virology. 2004;320:23–39.
   PubMed Web of Science ®Google Scholar
• Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Advanced drug delivery reviews. 2007;59:810–21.
   PubMed Web of Science ®Google Scholar
• Drouin M, Cayer MP, Jung D. Adenovirus 5 and chimeric adenovirus 5/F35 employ distinct B-lymphocyte intracellular trafficking routes that are independent of their cognate cell surface receptor. Virology. 2010;401:305–13.
   PubMed Web of Science ®Google Scholar
• Samson M, Jung D. Intracellular trafficking and fate of chimeric adenovirus 5/F35 in human B lymphocytes. The journal of gene medicine. 2011;13:451–61.
   PubMed Web of Science ®Google Scholar
• Thomsen P, Roepstorff K, Stahlhut M, van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Molecular biology of the cell. 2002;13:238–50.
   PubMed Web of Science ®Google Scholar
• Tagawa A, Mezzacasa A, Hayer A, Longatti A, Pelkmans L, Helenius A. Assembly and trafficking of caveolar domains in the cell: caveolae as stable, cargo-triggered, vesicular transporters. The Journal of cell biology. 2005;170:769–79.
   PubMed Web of Science ®Google Scholar
• Cayer MP, Samson M, Bertrand C, Dumont N, Drouin M, Jung D. Suppression of protein phosphatase 2A activity enhances Ad5/F35 adenovirus transduction efficiency in normal human B lymphocytes and in Raji cells. Journal of immunological methods. 2012;376:113–24.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kang S, Song JJ, Kim JH. The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. International journal of oncology. 2013;42:1337–48.
   PubMed Web of Science ®Google Scholar
• Reddy PS, Ganesh S, Yu DC. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12:2869–78.
   PubMed Web of Science ®Google Scholar
• Suominen E, Toivonen R, Grenman R, Savontaus M. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. The journal of gene medicine. 2006;8:1223–31.
   PubMed Web of Science ®Google Scholar
• Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. The journal of gene medicine. 2007;9:764–78.
   PubMed Web of Science ®Google Scholar
• Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. The journal of gene medicine. 2009;11:477–85.
   PubMed Web of Science ®Google Scholar
• Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer research. 2007;67:8783–90.
   PubMed Web of Science ®Google Scholar
• Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, Qian W. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Molecular cancer therapeutics. 2009;8:1387–97.
   PubMed Web of Science ®Google Scholar
• Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY, Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH, et al. Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget. 2014;5:5403–15.
   PubMed Web of Science ®Google Scholar
• Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, et al. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer letters. 2011;307:93–103.
   PubMed Web of Science ®Google Scholar
• He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M, et al. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Human gene therapy. 2011;22:283–92.
   PubMed Web of Science ®Google Scholar
• Fang L, Cheng Q, Liu W, Zhang J, Ge Y, Zhang Q, Li L1, Liu J, Zheng J. Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. Cancer biology & therapy. 2016;17:664–73.
   PubMed Web of Science ®Google Scholar
• Toivonen R, Suominen E, Grenman R, Savontaus M. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Oncology reports. 2009;21:165–71.
   PubMed Web of Science ®Google Scholar
• Kanno T, Gotoh A, Nakano T, Tagawa M, Nishizaki T. Beneficial oncolytic effect of fiber-substituted conditionally replicating adenovirus on human lung cancer. Anticancer research. 2012;32:4891–5.
   PubMed Web of Science ®Google Scholar
• Gotoh A, Kanno T, Nagaya H, Nakano T, Tabata C, Fukuoka K, Tagawa M, Nishizaki T. Gene therapy using adenovirus against malignant mesothelioma. Anticancer research. 2012;32:3743–7.
   PubMed Web of Science ®Google Scholar
• Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N, Kubo S. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer science. 2013;104:1433–9.
   PubMed Web of Science ®Google Scholar
• Gotoh A, Nagaya H, Kanno T, Tagawa M, Nishizaki T. Fiber-substituted conditionally replicating adenovirus Ad5F35 induces oncolysis of human bladder cancer cells in in vitro analysis. Urology. 2013;81:920 e7-11.
   PubMed Web of Science ®Google Scholar
• Takagi-Kimura M, Yamano T, Tagawa M, Kubo S. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Cancer gene therapy. 2014;21:126–32.
   PubMed Web of Science ®Google Scholar
• Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. The Journal of investigative dermatology. 2008;128:988–98.
   PubMed Web of Science ®Google Scholar
• Cho YS, Do MH, Kwon SY, Moon C, Kim K, Lee K, Lee SJ, Hemmi S, Joo YE, Kim MS. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. Oncotarget. 2016.
   Google Scholar
• Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, et al. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer gene therapy. 2009;16:383–92.
   PubMed Web of Science ®Google Scholar
• Xiang DB, Chen ZT, Wang D, Li MX, Xie JY, Zhang YS, Qing Y, Li ZP, Xie J. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer gene therapy. 2008;15:625–35.
   PubMed Web of Science ®Google Scholar